Endocrine Abstracts

Introduction: Dopamine agonists (DA), reference treatment for microprolactinomas, rarely allow long term remission. The performance of endoscopic pituitary surgery should be examined as first-line treatment.Objective: To evaluate the remission rate of microprolactinoma operated by endoscopic transphenoidal approachMethods: We retrospectively studied the surgical results of the 35 microprolactinomas operated between 2010 to 2017 in ...

TSH secreting pituitary adenomas are rare tumours for which the treatment of choice is neurosurgery but in some cases medical treatment with somatostatin analogs (SSA) can lead to a good control of symptoms and shrinkage of the tumour.The objective of this study was to review 30 patients diagnosed with TSH-omas between October 1981–July 2014, followed-up for a median of 43.93 months (1.12–192.11) in our University Hospital from Lyon, France.</p...

Introduction: Silent somatotroph tumours are GH immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. In our series, they represent 16% of all the somatotroph pituitary tumours. The aim of our study was to compare the somatotroph tumours with and without acromegaly to a better characterization of these silent tumours.Materials and methods: Fifty-nine tumours with acromegaly and 21 silent somatotroph tumours were studi...

Introduction: In the era of personalized patient management in acromegaly, transsphenoidal surgery remains a treatment of choice in cases where surgical cure can be expected. In order to better target these patients and to assess the risk of persistence/progression disease, we evaluated clinical, hormonal, radiological and pathological predictors of surgical outcome in acromegaly.Methods: A single-institution retrospective study from 2009 to 2015 was per...

Objective: The management of pituitary apoplexy, a rare emergency neuroendocrine condition, is controversial. The aim of the present study was to compare the outcome of patients with pituitary apoplexy managed either by a conservative or surgical approach.Methods: A retrospective cohort study including patients diagnosed between 2007 and 2018 in a tertiary French university hospital. Pituitary apoplexy score was retrospectively applied in a perspective o...

Background: Medical treatment of pituitary adenomas with somatostatin analogs depends on tumor type and somatostatin receptor expression. Using polyclonal antibodies, their immunohistochemical (IHC) detection gave conflicting results. Therefore, we studied the IHC expression of SSTR2A and SSTR5 using two specific MABs in five types of pituitary adenomas.Methods: SSTR2A and SSTR5 expression was studied using two...

Objective: Silent corticotroph adenomas (SCA) are rare pituitary tumours immunoreactive for ACTH but without clinical evidence of Cushing’s disease. They have been compared to non functioning pituitary adenomas or ACTH adenomas with Cushing’s disease, but no distinction has been made between micro and macro ACTH-adenomas. We characterize SCA on clinical, hormonal and molecular data and compared the characteristic of these tumours with those of macro (MCA) and micro A...

Gonadotroph pituitary tumors (GnPiT) account for ~40% of pituitary tumors surgically treated and 70-75% of non-functional pituitary tumors. Functional gonadotropin-secreting tumors are rare and clinical manifestations vary according to the age and sex of the patient. They are benign tumors which, due to their silent nature, can grow and invade surrounding structures, making complete resection impossible and leading to recurrence in ~30% of cases.Objectiv...

Introduction: Pituitary Neuroendocrine tumours (PitNETs) present heterogenic characteristics based on their hormonal expression and secretion. While most PitNETs have a slow progression rate, a subset of them exhibit an aggressive behaviour with recurrence properties despite current surgery, radio- and chemotherapy. To explore new clinical strategies based on immunotherapy we initiated a systemic cartography of the pituitary tumour immune microenvironment (PiTME).<p class=...

Background: Tumour microenvironment (TME) can comprise >50% of the tumour mass and includes non-tumour cells like immune cells and fibroblasts, as well as extracellular matrix, signaling molecules, and blood and lymph vessels. In recent years, TME has begun to be considered both a prognostic tool and a therapeutic target. While the existence of TME is well accepted and described in numerous cancers, little is known about the TME of pituitary neuroendocrine tumours (PitNETs...